(4S,5R)-4-isopropyl-5-methyl oxazolidinone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 英文名称: (4S,5R)-4-isopropyl-5-methyl oxazolidinone
• 英文别名: (4S,5R)-5-methyl-4-propan-2-yl-1,3-oxazolidin-2-one
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: DXKWZMBVJVXZPZ-RITPCOANSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (4S)-4-异丙基-5,5-二甲基-1,3-恶唑烷-2-硫酮 在 四氧化锇 sodium tetrahydroborate 、 sodium periodate 、 sodium hydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 为溶剂， 生成 (4S,5R)-4-isopropyl-5-methyl oxazolidinone
  参考文献：
  名称：

  Synthesis of N-substituted 2,4-thiazolidinediones from oxazolidinethiones

  摘要：

  A novel reaction has been found between oxazolidinethione and bromoacetyl bromide to afford N-substituted 2,4-thiazolidinediones through an intramolecular nucleophilic substitution reaction. Interestingly a step of elimination was carried out in trisubstituted oxazolidinethiones forming a double bond. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.09.116

文献信息

• Versatile Cp*Co(III)(LX) Catalyst System for Selective Intramolecular C–H Amidation Reactions
  作者：Jia Lee、Jeonghyo Lee、Hoimin Jung、Dongwook Kim、Juhyeon Park、Sukbok Chang

  DOI：10.1021/jacs.0c04448

  日期：2020.7.15

  Herein, we report the development of a tailored cobalt catalyst system of Cp*Co(III)(LX) toward intramolecular C-H nitrene insertion of azidoformates to afford cyclic carbamates. The cobalt complexes were easy to prepare and bench-stable, thus offering a convenient reaction protocol. The catalytic reactivity was significantly improved by the electronic tuning of the bidentate LX ligands, and the observed

  在此，我们报告了针对叠氮甲酸酯的分子内 CH 氮烯插入以提供环状氨基甲酸酯的 Cp*Co(III)(LX) 定制钴催化剂系统的开发。钴配合物易于制备且在实验室中稳定，因此提供了方便的反应方案。双齿LX配体的电子调谐显着提高了催化反应性，并且通过构象分析和过渡态的DFT计算使观察到的区域选择性合理化。新开发的钴催化剂体系的优异性能可广泛应用于温和条件下的 C(sp2)-H 和 C(sp3)-H 氨基甲酸化反应。
• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。
• Novel rearrangement of N-enoyl oxazolidinethiones to N-substituted 1,3-thiazine-2,4-diones promoted by NbCl5
  作者：Hector Hernández、Sylvain Bernès、Leticia Quintero、Estibaliz Sansinenea、Aurelio Ortiz

  DOI：10.1016/j.tetlet.2005.12.019

  日期：2006.2

  NbCl5 has been employed as promoter of a novel rearrangement to afford chiral N-substituted 1,3-thiazine-2,4-diones with one or two new stereogenic centers from di- and trisubstituted N-enoyl oxazolidinethiones. The trisubstituted E-isomers provide the anti-diastereomers mainly.

  NbCl 5已被用作新型重排的促进剂，以提供具有一个或两个来自二和三取代的N-烯酰基恶唑烷硫酮的新的立体异构中心的手性N-取代的1,3-噻嗪-2,4-二酮。三取代的E-异构体主要提供抗-非对映异构体。
• BICYCLIC AND TRICYCLIC DERIVATIVES AS THROMBIN RECEPTOR ANTAGONISTS
  申请人：Chackalamannil Samuel

  公开号：US20120157403A1

  公开（公告）日：2012-06-21

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bond, the dotted line is optionally a bond or no bond, resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.
• US8153664B2
  申请人：——

  公开号：US8153664B2

  公开（公告）日：2012-04-10